Sep 11th 2013 - Edison Investment Research today published a report on Lombard Medical Technologies (LMT.L, LSE:LMT, LON:LMT) entitled "Aorfix US Launch Underway". In summary, the report says:
Commercial revenue from Aorfix, the high-angle endograft for the repair of abdominal aortic aneurysms (AAA), returned to growth in H113 and its US launch has the potential to transform Lombard. Over 50% of minimally invasive AAA repair procedures via EVAR are performed in the US and the unique high-angle label (over 60º) is a key competitive advantage. Approval in Japan, the second-largest global market, is on track for H114 through a partner with strong physician relationships. We have increased our valuation from £98m to £119m following the recent fund-raising.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »